+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Latest Development, Product Innovations, and Treatments for Diabetes

  • PDF Icon

    Report

  • 166 Pages
  • September 2026
  • Region: Global
  • BCC Research
  • ID: 6290897
Description Jump to:
The report provides an overview of the global market for latest developments, product innovations, and treatments for diabetes. It includes global revenue ($ million) using 2025 as the base year, estimated data for 2026, and projected data for 2026 through 2031.

By product, the market is segmented into diabetic pharmaceuticals, glucose monitoring device technologies, and insulin delivery device technologies. Diabetic pharmaceuticals comprise injectable therapies and oral antidiabetic drugs (OADs). Glucose monitoring device technologies cover blood glucose test strips (BGTS), blood glucose meters, continuous glucose monitoring (CGM) systems, and lancets and lancet devices. Insulin delivery device technologies include insulin pens and needles, insulin pumps, and insulin syringes. By region, the market is segmented into North America (U.S., Canada, Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, focusing on all major countries within these regions.

This study focuses on the driving trends and challenges that affect the market and vendor landscape. It discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and providing leading companies in diabetes therapy, glucose monitoring devices, and insulin delivery devices in the market. It also contains a dedicated section of company profiles that covers company overviews, key financials, product portfolios, and recent developments.

The report includes:

  • 116 data tables and 69 additional tables
  • An analysis of the current and future global markets for diabetes treatment products and therapeutic innovations
  • Analyses of the global market trends, with historic data from 2023 to 2025, estimates for 2026 and projections of CAGRs through 2031
  • Estimates of the market size and revenue prospects for the global market, accompanied by a market share analysis by product category, device type, route of administration, and region
  • Facts and figures pertaining to the market dynamics, recent technological advancements in diabetes management, regulations, prospects and the impact of macroeconomic variables
  • Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
  • Review of emerging technologies, clinical trials, product and therapeutic innovations and pipeline analysis
  • Patent review, featuring key granted and published patents
  • Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • Company profiles of major players within the industry, including Abbott, Dexcom Inc., Lilly, Medtronic, and Novo Nordisk A/S

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
  • Overview
  • Current Market Scenario
  • Segmental Analysis
  • Regional Analysis
  • Technological Advances
  • Conclusion
Chapter 2 Market Overview
  • Overview
  • Epidemiology of Diabetes
  • Regional Distribution
  • Gender Distribution
  • Porter's Five Forces Analysis in the Market for Latest Developments, Product Innovations, and Treatments for Diabetes
  • Potential for New Entrants (Low to Moderate)
  • Bargaining Power of Suppliers (Low to Moderate)
  • Bargaining Power of Buyers (High)
  • Threat of Substitutes (Low)
  • Competition in the Industry (Low to Moderate)
  • Macroeconomic Factor Analysis
  • Healthcare Spending
  • Insurance Coverage and Reimbursement Policies
  • U.S. Tariff Scenario
Chapter 3 Market Dynamics
  • Market Dynamics
  • Market Drivers
  • Increasing Incidence of Type 1 and Type 2 Diabetes Driven by Urbanization
  • Growing Geriatric Population
  • Government Initiatives, Screening Programs, and Reimbursement Expansions
  • Market Restraints
  • Stringent Regulatory and Clinical Validation Requirements
  • Limited Healthcare Access in Low- and Middle-Income Countries
  • Market Opportunities
  • Strategic Collaborations between Pharma, Device, and Digital Health Companies
  • Digital Therapeutics and Remote Patient Management Platforms
Chapter 4 Regulatory Landscape
  • U.S.
  • Anti-Diabetes Drugs
  • Diabetes Therapeutic and Diagnostic Devices
  • Europe
  • Anti-Diabetic Drug
  • Diabetic Therapeutic and Diagnostic Devices
  • Other Regions
  • Anti-Diabetic Drugs
  • Diabetic Diagnostics and Therapeutics Devices
Chapter 5 Emerging Technologies and Developments
  • Emerging Technologies
  • Next-Generation Insulin Delivery Systems
  • Non-Invasive Glucose Monitoring
  • Artificial Intelligence
  • Analysis of Clinical Trials
  • Key Takeaways
  • Analysis of Clinical Trials by Type of Study
  • Clinical Trials Analysis by Status
  • Clinical Trials Analysis by Phase
  • Patent Analysis
  • Key Takeaways
  • Patents by Year
  • By Leading Applicant
  • By Leading Patent Owner
  • By Jurisdiction
Chapter 6 Market Segment Analysis
  • Segmentation Breakdown
  • Market Analysis by Product
  • Key Takeaways
  • Diabetes Pharmaceuticals
  • Glucose Monitoring Device Technologies
  • Insulin Delivery Device Technologies
  • Geographic Breakdown
  • Market Analysis by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa (MEA)
  • South America
Chapter 7 Competitive Intelligence
  • Key Takeaways
  • Competitive Landscape
  • Leading Companies
  • Lilly
  • Novo Nordisk A/S
  • Abbott
  • Dexcom Inc.
  • Insulet Corp.
  • Medtronic
  • Key Developments and Strategies
Chapter 8 Appendix
  • Methodology
  • Sources
  • Abbreviations
Company Profiles
  • ABBOTT
  • ACON Laboratories Inc.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • B. BRAUN SE
  • DEXCOM INC.
  • EMBECTA CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • INSULET CORP.
  • LILLY
  • MEDTRONIC
  • NOVO NORDISK A/S
  • SENSEONICS
  • TANDEM DIABETES CARE INC.
  • TERUMO CORP.
  • YPSOMED
  • Few Emerging Startups/Market Disruptors
List of Tables
Summary Table: Global Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Region, Through 2031
Table 1: Global and Regional Prevalence of Diabetes (Ages 20 to 79), by Region, 2024 Versus 2050
Table 2: Porter’s Five Forces Analysis: Overview
Table 3: Global: Diabetes Related Expenditure, By Region, 2024
Table 4: Global Estimates and Projections of Numbers and Prevalence of Adults (Aged 20+) With High BMI, by Sex, 2010, 2015, and 2030
Table 5: Diabetes: Geriatric Overview, 2024 and 2050
Table 6: Geriatric Diabetes Management
Table 7: Undiagnosed Diabetes by World Bank Income Classification, 2025
Table 8: Diabetes: Industry Collaborations, 2024-2026
Table 9: Technology Integrated Products
Table 10: FDA Medical Device Classification
Table 11: EU MDR Medical Device Classification
Table 12: Other Region: Diabetic Medical Device Regulatory Landscape
Table 13: Non-Invasive Glucose Monitoring Systems
Table 14: Number of Clinical Trials in Diabetes, by Type of Study, April 2026
Table 15: Number of Clinical Trials in Diabetes, by Status, April 2026
Table 16: Number of Clinical Trials in Diabetes, by Phase, April 2026
Table 17: Number of Patent Applications, by Leading Applicant, 2023-2025
Table 18: Number of Patents, by Top Patent Holder, 2023-2025
Table 19: Number of Patents, by Jurisdiction, 2023-2025
Table 20: Global Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 21: Global Market for Diabetic Pharmaceuticals, by Region, Through 2031
Table 22: Global Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 23: Global Market for Injectable Therapies, by Region, Through 2031
Table 24: Oral Antidiabetic Drugs Overview
Table 25: Global Market for Oral Antidiabetic Drugs, by Region, Through 2031
Table 26: Global Market for Glucose Monitoring Device Technologies, by Region, Through 2031
Table 27: Global Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 28: Continuous Glucose Monitoring (CGM) Systems Used in Diabetes Management
Table 29: Global Market for Continuous Glucose Monitoring Systems, by Region, Through 2031
Table 30: Global Market for Blood Glucose Test Strips (BGTS), by Region, Through 2031
Table 31: Global Market for Lancets and Lancet Devices, by Region, Through 2031
Table 32: Global Market for Blood Glucose Meters, by Region, Through 2031
Table 33: Global Market for Insulin Delivery Device Technologies, by Region, Through 2031
Table 34: Global Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 35: Global Market for Insulin Pens and Needles, by Region, Through 2031
Table 36: Global Market for Insulin Pumps, by Region, Through 2031
Table 37: Global Market for Insulin Syringes, by Region, Through 2031
Table 38: Global Market for Other Insulin Delivery Device Technologies, by Region, Through 2031
Table 39: Global Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Region, Through 2031
Table 40: North American Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Country, Through 2031
Table 41: North American Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 42: North American Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 43: North American Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 44: North American Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 45: U.S. Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 46: U.S. Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 47: U.S. Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 48: U.S. Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 49: Canadian Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 50: Canadian Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 51: Canadian Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 52: Canadian Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 53: Mexican Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 54: Mexican Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 55: Mexican Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 56: Mexican Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 57: European Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Country, Through 2031
Table 58: European Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 59: European Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 60: European Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 61: European Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 62: German Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 63: German Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 64: German Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 65: German Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 66: U.K. Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 67: U.K. Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 68: U.K. Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 69: U.K. Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 70: French Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 71: French Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 72: French Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 73: French Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 74: Italian Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 75: Italian Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 76: Italian Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 77: Italian Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 78: Spanish Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 79: Spanish Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 80: Spanish Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 81: Spanish Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 82: Rest of Europe Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 83: Rest of Europe Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 84: Rest of Europe Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 85: Rest of Europe Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 86: Asia-Pacific Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Country, Through 2031
Table 87: Asia-Pacific Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 88: Asia-Pacific Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 89: Asia-Pacific Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 90: Asia-Pacific Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 91: Chinese Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 92: Chinese Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 93: Chinese Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 94: Chinese Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 95: Japanese Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 96: Japanese Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 97: Japanese Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 98: Japanese Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 99: Indian Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 100: Indian Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 101: Indian Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 102: Indian Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 103: South Korean Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 104: South Korean Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 105: South Korean Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 106: South Korean Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 107: Australian Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 108: Australian Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 109: Australian Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 110: Australian Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 111: Rest of Asia-Pacific Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 112: Rest of Asia-Pacific Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 113: Rest of Asia-Pacific Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 114: Rest of Asia-Pacific Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 115: MEA Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 116: MEA Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 117: MEA Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 118: MEA Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 119: South American Market for Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, Through 2031
Table 120: South American Market for Diabetic Pharmaceuticals, by Type, Through 2031
Table 121: South American Market for Glucose Monitoring Device Technologies, by Type, Through 2031
Table 122: South American Market for Insulin Delivery Device Technologies, by Type, Through 2031
Table 123: Global Market Ranking of Leading Companies for Diabetes Therapies, 2025
Table 124: Global Market Leading Companies for Glucose Monitoring Devices, 2025
Table 125: Ranking of Leading Companies for Insulin Delivery Devices, 2025
Table 126: Recent Strategic Developments in Global Market for Latest Developments, Product Innovations, and Treatments for Diabetes, 2025-2026
Table 127: Report Information Sources
Table 128: Abbreviations Used in This Report
Table 129: Abbott: Company Snapshot
Table 130: Abbott: Financial Performance, FY 2024 and 2025
Table 131: Abbott: Product Portfolio
Table 132: Abbott: News/Key Developments, 2024-2025
Table 133: ACON Laboratories Inc.: Company Snapshot
Table 134: ACON Laboratories Inc.: Product Portfolio
Table 135: Boehringer Ingelheim International GmbH: Company Snapshot
Table 136: Boehringer Ingelheim International GmbH: Financial Performance, FY 2024 and 2025
Table 137: Boehringer Ingelheim International GmbH: Product Portfolio
Table 138: B. Braun SE: Company Snapshot
Table 139: B. Braun SE: Financial Performance, FY 2024 and 2025
Table 140: B. Braun SE: Product Portfolio
Table 141: Dexcom Inc.: Company Snapshot
Table 142: Dexcom Inc.: Financial Performance, FY 2024 and 2025
Table 143: Dexcom Inc.: Product Portfolio
Table 144: Dexcom Inc.: News/Key Developments, 2024-2026
Table 145: Embecta Corp.: Company Snapshot
Table 146: Embecta Corp.: Financial Performance, FY 2024 and 2025
Table 147: Embecta Corp.: Product Portfolio
Table 148: Embecta Corp.: News/Key Developments, 2024
Table 149: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 150: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2024 and 2025
Table 151: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 152: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024-2025
Table 153: Insulet Corp.: Company Snapshot
Table 154: Insulet Corp.: Financial Performance, FY 2024 and 2025
Table 155: Insulet Corp.: Product Portfolio
Table 156: Insulet Corp.: News/Key Developments, 2024-2026
Table 157: Lilly: Company Snapshot
Table 158: Lilly: Financial Performance, FY 2024 and 2025
Table 159: Lilly: Product Portfolio
Table 160: Lilly: News/Key Developments, 2024-2025
Table 161: Medtronic: Company Snapshot
Table 162: Medtronic: Financial Performance, FY 2023 and 2024
Table 163: Medtronic: Product Portfolio
Table 164: Medtronic: News/Key Developments, 2024-2026
Table 165: Novo Nordisk A/S: Company Snapshot
Table 166: Novo Nordisk A/S: Financial Performance, FY 2024 and 2025
Table 167: Novo Nordisk A/S: Product Portfolio
Table 168: Novo Nordisk A/S: News/Key Developments, 2024-2025
Table 169: Senseonics: Company Snapshot
Table 170: Senseonics: Financial Performance, FY 2024 and 2025
Table 171: Senseonics: Product Portfolio
Table 172: Senseonics: News/Key Developments, 2024-2026
Table 173: Tandem Diabetes Care Inc.: Company Snapshot
Table 174: Tandem Diabetes Care Inc.: Financial Performance, FY 2024 and 2025
Table 175: Tandem Diabetes Care Inc.: Product Portfolio
Table 176: Tandem Diabetes Care Inc.: News/Key Developments, 2025
Table 177: Terumo Corp.: Company Snapshot
Table 178: Terumo Corp.: Financial Performance, FY 2023 and 2024
Table 179: Terumo Corp.: Product Portfolio
Table 180: Ypsomed: Company Snapshot
Table 181: Ypsomed: Financial Performance, FY 2023 and 2024
Table 182: Ypsomed: Product Portfolio
Table 183: Ypsomed: News/Key Developments, 2025-2026
Table 184: List of a Few Emerging Startups/ Market Disruptors
List of Figures
Summary Figure: Global Market Shares of Latest Developments, Product Innovations, and Treatments for Diabetes, by Region, 2025
Figure 1: Porter’s Five Forces Analysis: Global Market for Latest Developments, Product Innovations, and Treatments for Diabetes
Figure 2: DIABETES: Type
Figure 3: Market Dynamics of Latest Developments, Product Innovations, and Treatments for Diabetes
Figure 4: Estimated Global Number of People Aged 20 to 79 With Diabetes, 2000-2024
Figure 5: Emerging Trends/Technologies in the Market for Latest Developments, Product Innovations, and Treatments for Diabetes
Figure 6: Number of Patents Granted, by Year, 2023-2025
Figure 7: Global Market Shares of Latest Developments, Product Innovations, and Treatments for Diabetes, by Product, 2025
Figure 8: Global Market Shares of Diabetic Pharmaceuticals, by Type, 2025
Figure 9: Global Market Shares of Glucose Monitoring Device Technologies, by Type, 2025
Figure 10: Global Market Shares of Insulin Delivery Device Technologies, by Type, 2025
Figure 11: Global Market Shares of Latest Developments, Product Innovations, and Treatments for Diabetes, by Region, 2025
Figure 12: North American Market Shares of Latest Developments, Product Innovations, and Treatments for Diabetes, by Country, 2025
Figure 13: European Market Shares of Latest Developments, Product Innovations, and Treatments for Diabetes, by Country, 2025
Figure 14: Asia-Pacific Market Shares of Latest Developments, Product Innovations, and Treatments for Diabetes, by Country, 2025
Figure 15: ABBOTT: Revenue Shares, by Business Unit, FY 2025
Figure 16: ABBOTT: Revenue Shares, by Country/Region, FY 2025
Figure 17: Boehringer Ingelheim International GmbH: Revenue Shares, by Business Unit, FY 2025
Figure 18: Boehringer Ingelheim International GmbH: Revenue Shares, by Country/Region, FY 2025
Figure 19: B. Braun SE: Revenue Shares, by Business Unit, FY 2025
Figure 20: B. Braun SE: Revenue Shares, by Country/Region, FY 2025
Figure 21: Dexcom Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 22: Embecta Corp.: Revenue Shares, by Country/Region, FY 2025
Figure 23: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2025
Figure 24: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2025
Figure 25: Insulet Corp.: Revenue Shares, by Business Unit, FY 2025
Figure 26: Insulet Corp.: Revenue Shares, by Country/Region, FY 2025
Figure 27: LILLY: Revenue Shares, by Country/Region, FY 2025
Figure 28: MEDTRONIC: Revenue Shares, by Business Unit, FY 2024
Figure 29: MEDTRONIC: Revenue Shares, by Country/Region, FY 2024
Figure 30: Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2025
Figure 31: Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2025
Figure 32: SENSEONICS: Revenue Shares, by Country/Region, FY 2025
Figure 33: Tandem Diabetes Care Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 34: Tandem Diabetes Care Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 35: Terumo Corp.: Revenue Shares, by Business Unit, FY 2024
Figure 36: Terumo Corp.: Revenue Shares, by Country/Region, FY 2024
Figure 37: YPSOMED: Revenue Shares, by Business Unit, FY 2024
Figure 38: YPSOMED: Revenue Shares, by Country/Region, FY 2024

Executive Summary

The global market for latest developments, product innovations, and treatments for diabetes was valued at $144.5 billion in 2025 and is estimated to increase from $162.2 billion in 2026 to reach $295 billion by the end of 2031, at a compound annual growth rate (CAGR) of 12.7% from 2026 to 2031.

Companies Mentioned

  • ABBOTT
  • ACON Laboratories Inc.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • B. BRAUN SE
  • DEXCOM INC.
  • EMBECTA CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • INSULET CORP.
  • LILLY
  • MEDTRONIC
  • NOVO NORDISK A/S
  • SENSEONICS
  • TANDEM DIABETES CARE INC.
  • TERUMO CORP.
  • YPSOMED

Related Topics

Related Reports

Diabetes Therapeutics and Diagnostics - Product Image

Diabetes Therapeutics and Diagnostics

  • Report
  • 187 Pages
  • Global
From
China Diabetes Care Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

China Diabetes Care Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 70 Pages
  • China
From
Global Diabetes Care Market Analysis 2026-2031 - Product Image

Global Diabetes Care Market Analysis 2026-2031

  • Report
  • 280 Pages
  • Global
From
Diabetes Management Software Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Diabetes Management Software Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Egypt Diabetes Care Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Egypt Diabetes Care Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 70 Pages
  • Egypt
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.